{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:16:02Z","timestamp":1794323762427,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key R&D Program (Social Development) Project of Jiangsu Province","award":["BE2021648"],"award-info":[{"award-number":["BE2021648"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The objective of this study was to evaluate the therapeutic effectiveness and safety of transarterial chemoembolization (TACE) combined with programmed cell death-1 (PD-1) inhibitors and lenvatinib in the treatment of unresectable intrahepatic cholangiocarcinoma (uICC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multicenter retrospective study screened patients with uICC who underwent TACE in combination with PD-1 inhibitors and lenvatinib between January 2019 and June 2023. Tislelizumab or camrelizumab (200\u2009mg) was intravenously administered every three weeks. The daily dose of lenvatinib was 8\u2009mg for patients weighing\u2009&lt;\u200960\u2009kg and 12\u2009mg for those weighing\u2009\u2265\u200960\u2009kg. In cases of disease progression, the therapeutic strategy was adjusted based on the clinical condition and individual patient\u2019s treatment preferences. Options included transitioning to standard or supportive care or continuing treatment with TACE in combination with PD-1 inhibitors and lenvatinib. The primary outcomes were overall survival (OS) and progression-free survival (PFS), while secondary outcomes included the objective response rate (ORR), disease control rate (DCR), and the incidence of adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 59 patients with uICC were included. Over a median follow-up period of 32.3 months, the median OS and PFS were 25.8 months (95% confidence interval [CI]: 17.9\u201333.7) and 9.5 months (95% CI: 7.9\u201311.0), respectively. The ORR was 55.9%, and the DCR was 96.6%. Grade 3 or four AEs were observed in 15 of 59 patients (25.4%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>TACE combined with PD-1 inhibitors and lenvatinib demonstrated a promising therapeutic potential with a manageable safety profile for patients with uICC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Relevance statement<\/jats:title>\n            <jats:p>The combination of TACE, PD-1 inhibitors, and lenvatinib represents a novel therapeutic option for patients with uICC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>TACE plus PD-1 inhibitors and lenvatinib represent a promising therapeutic strategy for uICC.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>The safety profile of TACE plus PD-1 inhibitors and lenvatinib was manageable.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>This study demonstrated improved outcomes compared to prior standard-of-care treatments.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s41747-025-00563-4","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:07:56Z","timestamp":1739898476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Jin-Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-0124","authenticated-orcid":false,"given":"Xiao-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"European Association for the Study of the Liver","year":"2023","unstructured":"European Association for the Study of the Liver (2023) EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol 79:181\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.010","journal-title":"J Hepatol"},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejso.2020.01.028","volume":"46","author":"N Machairas","year":"2020","unstructured":"Machairas N, Lang H, Jayant K, Raptis DA, Sotiropoulos GC (2020) Intrahepatic cholangiocarcinoma: limitations for resectability, current surgical concepts and future perspectives. Eur J Surg Oncol 46:740\u2013746. https:\/\/doi.org\/10.1016\/j.ejso.2020.01.028","journal-title":"Eur J Surg Oncol"},{"key":"563_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","volume":"16","author":"SKR Mukkamalla","year":"2018","unstructured":"Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA (2018) Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw 16:370\u2013376. https:\/\/doi.org\/10.6004\/jnccn.2017.7056","journal-title":"J Natl Compr Canc Netw"},{"key":"563_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.23781","volume":"111","author":"LM Boehm","year":"2015","unstructured":"Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213\u2013220. https:\/\/doi.org\/10.1002\/jso.23781","journal-title":"J Surg Oncol"},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"563_CR6","doi-asserted-by":"publisher","unstructured":"Owen M, Makary MS, Beal EW (2023) Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers. https:\/\/doi.org\/10.3390\/cancers15082384","DOI":"10.3390\/cancers15082384"},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX (2020) Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol 72:353\u2013363. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.009","journal-title":"J Hepatol"},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM et al (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13:181\u2013188. https:\/\/doi.org\/10.1016\/S1470-2045(11)70301-1","journal-title":"Lancet Oncol"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","volume":"4","author":"MA Lowery","year":"2019","unstructured":"Lowery MA, Burris HA, 3rd Janku F et al (2019) Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 4:711\u2013720. https:\/\/doi.org\/10.1016\/S2468-1253(19)30189-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"563_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS et al (2023) Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther 8:58. https:\/\/doi.org\/10.1038\/s41392-022-01235-0","journal-title":"Signal Transduct Target Ther"},{"key":"563_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1138355","volume":"14","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhu X, Liu J et al (2023) Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study. Front Immunol 14:1138355. https:\/\/doi.org\/10.3389\/fimmu.2023.1138355","journal-title":"Front Immunol"},{"key":"563_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1751-2980.13127","volume":"23","author":"N Zhang","year":"2022","unstructured":"Zhang N, Yu BR, Wang YX et al (2022) Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis 23:535\u2013545. https:\/\/doi.org\/10.1111\/1751-2980.13127","journal-title":"J Dig Dis"},{"key":"563_CR13","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z, Xie L, Yan X et al (2023) Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol 96:20230079. https:\/\/doi.org\/10.1259\/bjr.20230079","journal-title":"Br J Radiol"},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"563_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","volume":"10","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao M, Arai Y et al (2021) Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr 10:661\u2013671. https:\/\/doi.org\/10.21037\/hbsn-21-260","journal-title":"Hepatobiliary Surg Nutr"},{"key":"563_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z et al (2020) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer 9:682\u2013720. https:\/\/doi.org\/10.1159\/000509424","journal-title":"Liver Cancer"},{"key":"563_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"563_CR19","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"563_CR20","first-page":"6584","volume":"12","author":"Y Hu","year":"2020","unstructured":"Hu Y, Hao M, Chen Q, Chen Z, Lin H (2020) Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma. Am J Transl Res 12:6584\u20136598","journal-title":"Am J Transl Res"},{"key":"563_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G et al (2021) Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma\u2014a systemic review and meta-analysis. Cardiovasc Intervent Radiol 44:728\u2013738. https:\/\/doi.org\/10.1007\/s00270-021-02800-w","journal-title":"Cardiovasc Intervent Radiol"},{"key":"563_CR22","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.7150\/jca.39410","volume":"11","author":"TY Zhou","year":"2020","unstructured":"Zhou TY, Zhou GH, Zhang YL et al (2020) Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 11:4534\u20134541. https:\/\/doi.org\/10.7150\/jca.39410","journal-title":"J Cancer"},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.7150\/jca.67523","volume":"13","author":"T Sun","year":"2022","unstructured":"Sun T, Zhang W, Chen L et al (2022) A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients. J Cancer 13:1282\u20131288. https:\/\/doi.org\/10.7150\/jca.67523","journal-title":"J Cancer"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00270-009-9694-4","volume":"32","author":"G Poggi","year":"2009","unstructured":"Poggi G, Amatu A, Montagna B et al (2009) OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32:1187\u20131192. https:\/\/doi.org\/10.1007\/s00270-009-9694-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"563_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940009","volume":"13","author":"XG Yang","year":"2022","unstructured":"Yang XG, Sun YY, Li DS, Xu GH, Huang XQ (2022) Efficacy and safety of drug-eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Front Immunol 13:940009. https:\/\/doi.org\/10.3389\/fimmu.2022.940009","journal-title":"Front Immunol"},{"key":"563_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","volume":"4","author":"A Schicho","year":"2016","unstructured":"Schicho A, Hellerbrand C, Kruger K et al (2016) Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol 4:288\u2013292. https:\/\/doi.org\/10.14218\/JCTH.2016.00058","journal-title":"J Clin Transl Hepatol"},{"key":"563_CR27","doi-asserted-by":"publisher","unstructured":"Pinato DJ, Murray SM, Forner A et al (2021) Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003311","DOI":"10.1136\/jitc-2021-003311"},{"key":"563_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L et al (2021) Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18:293\u2013313. https:\/\/doi.org\/10.1038\/s41575-020-00395-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"563_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202401304","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Fang Z, Pan D et al (2024) Dendritic polymer-based nanomedicines remodel the tumor stroma: improve drug penetration and enhance antitumor immune response. Adv Mater 36:e2401304. https:\/\/doi.org\/10.1002\/adma.202401304","journal-title":"Adv Mater"},{"key":"563_CR30","doi-asserted-by":"publisher","unstructured":"Chen X, Wu X, Wu H et al (2020) Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001240","DOI":"10.1136\/jitc-2020-001240"},{"key":"563_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1183\/09059180.00004214","volume":"23","author":"J Menis","year":"2014","unstructured":"Menis J, Hasan B, Besse B (2014) New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev 23:367\u2013378. https:\/\/doi.org\/10.1183\/09059180.00004214","journal-title":"Eur Respir Rev"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-025-00563-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:08:00Z","timestamp":1739898480000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurradiolexp.springeropen.com\/articles\/10.1186\/s41747-025-00563-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1186\/s41747-025-00563-4","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Ethics Review Board of the First Affiliated Hospital of Soochow University approved the study (date: 2024.07.10, no. 2024-361). Written informed consent was waived by the Institutional Review Board due to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}